Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access